Compare AMETEK, Inc. (AME) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Ascendis Pharma A/S — how do they compare? AMETEK, Inc. trades at $256.71 (market cap $58.76B), while Ascendis Pharma A/S trades at $255.71 (market cap $16.67B). The key difference: AMETEK, Inc. is far larger — about 3.5× Ascendis Pharma A/S's market cap, and AMETEK, Inc. pays a 0.53% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| AME | ASND | |
|---|---|---|
Market Cap | $58.76B | $16.67B |
Sector | Industrials | Health |
52-Week High | $256.30 | $277.18 |
52-Week Low | $179.28 | $189.74 |
Enterprise Value | $60.30B | $17.04B |
Dividend Yield | 0.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $252.88, down 0.31% on the day, with a bullish technical signal from moving averages and strong support near $252. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance, reflecting robust demand. Revenue grew to $7.4B in 2025, with a net margin of 20.04%, while valuation ratios like P/E of 37.47 suggest a premium. Recent news highlights momentum and inclusion in high-growth themes like 3D printing.
Outlook remains positive given earnings beats and analyst consensus, but risks include elevated valuation and macroeconomic sensitivity. The stock offers growth potential with a $281.86 price target, though investors should monitor execution against guidance and industry competition.
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
